MedAlliance Secures $50M To Aid Trials And Commercialization
Trustar Capital’s investment will allow MedAlliance to pursue commercialization of its drug eluting balloon and further its trial efforts.
You may also be interested in...
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations in the last two months. Part II of this month’s update includes innovative research and development news from smaller companies and research labs that you may have missed.
SELUTION SLR is the first drug-eluting balloon accepted by the FDA as part of its breakthrough program, according to the company.